0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letter |

Use of Cardiac Implantable Electronic Devices in Older Adults With Cognitive Impairment FREE

Nicole R. Fowler, PhD, MHSA1; Kim G. Johnson, MD2; Jie Li, MS3; Charity G. Moore, PhD1,3; Samir Saba, MD4; Oscar L. Lopez, MD5; Amber E. Barnato, MD, MPH, MS1
[+] Author Affiliations
1Division of General Internal Medicine, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
2Department of Psychiatry, Duke University Medical Center, Durham, North Carolina
3Center for Research on Health Care, University of Pittsburgh, Pittsburgh, Pennsylvania
4Division of Cardiology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
5Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
JAMA Intern Med. 2014;174(9):1514-1516. doi:10.1001/jamainternmed.2014.3450.
Text Size: A A A
Published online

Older adults with mild cognitive impairment (MCI) and dementia have cardiac comorbidities, making them eligible for device-based therapy for cardiac rhythm abnormalities.13 The risks and benefits of device implantation should be weighed carefully by patients with cognitive impairment, family members, and clinicians given the potential of these devices to have an impact on the quantity and quality of life. This study describes the epidemiology of cardiac implantable electronic devices among a population-based sample of older adults with and without cognitive impairment.

We conducted a retrospective cohort study of deidentified data from the National Alzheimer Coordinating Center Uniform Data Set4 gathered prospectively from 33 Alzheimer Disease Centers (ADCs) from September 2005 through December 2011. The institutional review board of the University of Pittsburgh approved the study. The sample included participants with a baseline ADC visit and at least 1 follow-up visit during the study period. Participants without cognitive impairment included ADC normal controls and participants who had minor deficits on cognitive testing but did not meet criteria for MCI or dementia. The dependent variable was incident (new) device, assessed at each ADC visit as determined by the clinician’s best judgment based on informant report, medical records, and observation. The independent variable was cognitive status, measured by ADC diagnosis and Clinical Dementia Rating (CDR) Scale.5

We fitted generalized estimating equation models with a binomial distribution and logit link function accounting for cognitive status and CDR the visit before the device was implanted and for multiple pairs of consecutive visits for each participant allowing for time-varying cognitive status. We used a multiple comparison Bonferroni correction to compare each level of the independent variable to the group without cognitive impairment and adjusted for age, sex, race, intensity of pacemaker use in the ADC hospital referral region,6 as well as time-varying health status, cardiac comorbidity burden, functional status, and Hachinski Ischemic Score.

There were 16 245 participants with a baseline visit and at least 1 follow-up visit in the study period. At baseline 7446 (45.8%) had no cognitive impairment, 3460 (21.3%) had MCI, and 5339 (32.9%) had dementia. Participants with cognitive impairment were significantly older and more likely to be male and to have ischemic heart disease and stroke. However, they had similar rates of atrial fibrillation and congestive heart failure (Table 1). Over the 7-year study period, rates of incident pacemakers were 4 per 1000 person-years for participants without cognitive impairment, 4.7 per 1000 person-years for participants with MCI, and 6.5 per 1000 person-years for participants with dementia (P = .001) (Table 2). Incidence of implantable cardioverter-defibrillators in all cognitive groups was low (≤0.5 per 1000 person-years) and prohibited multivariable modeling.

Table Graphic Jump LocationTable 1.  Baseline Demographics by Cognitive Status
Table Graphic Jump LocationTable 2.  Impact of Cognitive Status on Receipt of Incident Pacemaker

In adjusted models, participants with dementia the visit before assessment for an incident pacemaker were 1.6 (95% CI, 1.1-2.5) times more likely to receive a pacemaker compared with participants without cognitive impairment (P = .02) (Table 2). In the model that accounted for cognitive status over consecutive visits, participants with stable dementia were 1.8 (95% CI, 1.2-2.8) times more likely (P < .01) to receive a pacemaker compared with those without cognitive impairment (Table 2). In a separate model for severity of cognitive impairment, participants with a CDR of 3 (severe dementia) were 2.9 (95% CI, 1.2-7.4) more likely to receive a pacemaker than those with a CDR of 0 (no cognitive impairment) (P = .02) (Table 2).

Patients with dementia were more likely to receive a pacemaker than patients without cognitive impairment, even after adjusting for clinical risk factors. This runs counter to the normative expectation that patients with a serious life-limiting and cognitively disabling illness might be treated less aggressively. While it is possible that unmeasured confounding by indication explains this observation, future research should explore the patient, caregiver, and clinician influences on decision making regarding cardiac devices in this population.

Corresponding Author: Nicole R. Fowler, PhD, MHSA, Division of General Internal Medicine, Department of Medicine, School of Medicine, University of Pittsburgh, 200 Meyran Ave, Ste 300, Pittsburgh, PA 15213 (fowlernr@upmc.edu).

Published Online: July 28, 2014. doi:10.1001/jamainternmed.2014.3450.

Author Contributions: Drs Fowler and Barnato had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Fowler, Johnson, Saba, Lopez, Barnato.

Acquisition, analysis, or interpretation of data: Fowler, Li, Moore, Lopez, Barnato.

Drafting of the manuscript: Fowler, Johnson, Lopez, Barnato.

Critical revision of the manuscript for important intellectual content: Fowler, Li, Moore, Saba, Lopez, Barnato.

Statistical analysis: Fowler, Li, Moore.

Obtained funding: Fowler.

Administrative, technical, or material support: Fowler.

Study supervision: Fowler, Saba, Lopez, Barnato.

Conflict of Interest Disclosures: None reported.

Funding/Support: This study was supported by the Agency for Healthcare Research and Quality (AHRQ), grant K12HS019461, and National Institutes of Health (NIH), National Institute on Aging, grant P50 AG05133. The National Alzheimer Coordinating Center database is funded by the NIH, National Institute on Aging, grant UO1 AG016976.

Role of the Sponsor: The AHRQ and NIH had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Previous Presentations: This work was previously presented as a poster at the American Geriatrics Society Meeting; May 3, 2013; Grapevine, Texas; and at the Annual Meeting of the Society for Medical Decision Making; October 21, 2013; Baltimore, Maryland.

Additional Contributions: Sarah Monsell, MS, from the University of Washington and the National Alzheimer’s Coordinating Center, assisted with obtaining and interpreting the data and reviewed the manuscript. Greg Sachs, MD, from Indiana University School of Medicine, reviewed a final draft of this manuscript prior to submission. They were not compensated for their participation.

Launer  LJ.  Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev. 2002;1(1):61-77.
PubMed   |  Link to Article
DeCarli  C.  The role of cerebrovascular disease in dementia. Neurologist. 2003;9(3):123-136.
PubMed   |  Link to Article
Vermeer  SE, Prins  ND, den Heijer  T, Hofman  A, Koudstaal  PJ, Breteler  MMB.  Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348(13):1215-1222.
PubMed   |  Link to Article
National Alzheimer Coordinating Center Uniform Data Set (UDS) Coding Guidebook.https://www.alz.washington.edu/NONMEMBER/UDS/DOCS/VER2/ivpguide.pdf. Accessed October 18, 2013.
Morris  JC.  The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.
PubMed   |  Link to Article
Dartmouth Atlas of Health Care. http://www.dartmouthatlas.org/tools/downloads.aspx. Accessed April 23, 2012.

Figures

Tables

Table Graphic Jump LocationTable 1.  Baseline Demographics by Cognitive Status
Table Graphic Jump LocationTable 2.  Impact of Cognitive Status on Receipt of Incident Pacemaker

References

Launer  LJ.  Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev. 2002;1(1):61-77.
PubMed   |  Link to Article
DeCarli  C.  The role of cerebrovascular disease in dementia. Neurologist. 2003;9(3):123-136.
PubMed   |  Link to Article
Vermeer  SE, Prins  ND, den Heijer  T, Hofman  A, Koudstaal  PJ, Breteler  MMB.  Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348(13):1215-1222.
PubMed   |  Link to Article
National Alzheimer Coordinating Center Uniform Data Set (UDS) Coding Guidebook.https://www.alz.washington.edu/NONMEMBER/UDS/DOCS/VER2/ivpguide.pdf. Accessed October 18, 2013.
Morris  JC.  The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.
PubMed   |  Link to Article
Dartmouth Atlas of Health Care. http://www.dartmouthatlas.org/tools/downloads.aspx. Accessed April 23, 2012.

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

1,010 Views
0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs
×